Free Newsletter
FEATURES >> The most interesting logos in Pharma
J&J chief turns down pay raise
Behind Door No. 2 in executive compensation land, we find Johnson & Johnson CEO Bill Weldon (photo). The scoop lies within a filing with the Securities and Exchange Commission, but in this case it's not the sort of arrangement a company seeks to hide--especially not now, when the economy is in a recession and layoffs are the order of the day (J&J laid off some 5,000 folks in 2007).
The news? Weldon turned down a merit-pay increase in his base salary for 2009. The compensation committee had offered him the increase, but Weldon recommended that his base salary remain at $1.8 million "in recognition of the current global economic environment," the AP reports. For 2008 he'll reap a $3.5 million bonus, 85 percent of that in cash.
- read the AP story
- see the article in the Wall Street Journal
Related Articles:
J&J revenue sees first decline in 76 years
J&J's Bill Weldon - CEO Pay
The best of paychecks, the worst of paychecks...
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities



SHARE
WITH: